Why I’d buy this dividend-growing share alongside AstraZeneca

I like AstraZeneca plc (LON: AZN) but I’d also buy shares in this firm for its growing dividend and global ambitions.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Pharmaceutical giant AstraZeneca looks like it’s moving into a period of profit growth after several years of contracting earnings. New products and drugs emerging from the Research & Development pipeline have been powering the firm’s transformation.

However, in the wider healthcare sector, I also like the look of Cello Health (LSE: CLL), which operates as a healthcare-focused advisory company. City analysts following the firm have pencilled in high single-digit advances in earnings for this year and next, and much of the progress is coming from the firm’s fast-growing operations in the US.

Strong progress in the US

I last wrote about the company in March when we heard that the US part of the business had delivered 29% of overall revenues in 2018. However, today’s interim results report reveals to us that just over 34% of its net revenue came from US operations in the first six months of 2019, suggesting significant progress across the pond.

Overall revenue rose almost 7% compared to the equivalent period last year and adjusted earnings per share moved nearly 12.7% higher. Like-for-like revenue at constant currency rates notched up by 4.5%, indicating strong organic trading. At the halfway point in the year, Cello health declared net funds of £2.2m, which compares to a net debt figure of £5.4m six months earlier. Cash flow has been “strong”, the directors said in the report. They applied their seal of approval by pushing up the interim dividend by 4.5%. It seems to me the financial figures are moving in the right direction.

During the period, the company developed its new office in Berlin, which is now fully functioning and “servicing European clients”. It also acquired a firm in the US called ISS, which “strengthens” its advisory capability in America adding“critical regulatory expertise”. ISS is a scientific consulting firm specialising in strategic counsel and regulatory support for the healthcare industry, which is clearly a good fit with existing operations.

Global ambitions

The pursuit of growth remains very much on the agenda. Indeed, the goal is to build a “global” advisory company in the healthcare sector and, so far, that ambition seems to be on track. Cello Health reckons that 24 of the “top”25 global pharmaceutical businesses are already clients, as well as “a wide range of biotech and other clients”.

Meanwhile, operating profit received a boost of around £0.2m because of the strength of the dollar against sterling during the period. Looking forward, the directors expect that effect to continue for the rest of 2019, alongside ongoing strong cash inflow. And the firm plans to spend some of the money it’s making on growth-enhancing acquisitions. There is a pipeline of opportunities that the directors are already appraising.

With the share price close to 127p, the forward-looking earnings multiple for 2020 runs near 12.5 and the anticipated dividend yield is a little over 3.3%. I think the shares are attractive. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any share mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »